Finances

[biopearl123]

Geron has money in the bank, the ability to extend the loan and now an active shelf. Do they want the cushion to pay for the last two years of the study (IMbark) if the interim results mandate continuation (which it seems they anticipate) or do they want the cushion to pay for expenses associated with early to market if it is the interim results that mandate such an approach. If they are truly blinded to the results so far, even they don’t know, but I can’t believe that. Since only one IST is on the books with one institution (that may share or shoulder expenses), it’s unlikely to be that. If they break even as projected for 2026, it’s not for operating expenses either since they should have that. Anyone make sense of this?

[Zhears]

My first thought, or at least hope, was that it is another poison pill. The size of the shelf is extreme.
At least he didn't say they could use the money to buy another company.